Ceftax

Quick links to important sections

Ceftax

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceftax

What is Ceftax? Identity and Purpose Overview

The following provides a concise identity profile for Ceftax, detailing its composition and classification as an anti-infective agent.

Property Description
Active ingredient Cefotaxime (Cefotaxime sodium)
Form Powder for injection (reconstituted into solution)
Pharmacological class Third-generation cephalosporin antibiotic
Common use Broad-spectrum anti-infective
Origin Semisynthetic

What Type of Medicine is Ceftax (Cefotaxime)?

Ceftax is the trade name for a medicine containing the active ingredient Cefotaxime, a compound used as an antibiotic. Cefotaxime is classified specifically as a third-generation cephalosporin, which is a type of semisynthetic beta-lactam antibiotic.

This classification is characterized by providing enhanced stability against certain bacterial enzymes compared to earlier generations. Cefotaxime's formulation is a sterile powder for injection, a differentiating factor as it necessitates parenteral delivery—a route typically chosen for hospitalized patients or when immediate, high concentrations are required. Other commercial preparations sharing this identical composition include brands like Claforan and Tolycar.


What is the Purpose of Cefotaxime's Action?

The general purpose of Cefotaxime is to function as a broad-spectrum anti-infective agent, providing a tool to overcome serious infections caused by susceptible bacteria. The drug's action is bactericidal, meaning it kills the targeted pathogens rather than inhibiting their reproduction.

This effect is achieved by directly interfering with the process of bacterial cell wall synthesis. This mechanism is defined by a high affinity for the molecular targets within the bacterial cell wall structure. This action is typically reserved for challenging scenarios, such as certain systemic or localized infections requiring high-level intervention.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Ceftax?

Possible side effects and safety information

The official safety information for Ceftax (Cefotaxime) is categorized based on how frequently adverse reactions appear and which body systems they involve, as established by regulatory authorities.

Documented Adverse Reactions by Frequency

Classification Examples of Reactions Affected Systems
Common Diarrhea, rash, injection site reactions (pain, inflammation) Gastrointestinal, Skin, Local
Uncommon Hypersensitivity reactions, headache, dizziness, transient changes in blood cell counts (e.g., leukopenia, eosinophilia), elevated liver enzymes Immune System, Nervous System, Blood and Lymphatic, Hepatobiliary

Serious Adverse Reactions

Regulatory documents highlight the potential for serious adverse reactions, although they are generally rare. These include severe anaphylactic shock and other severe hypersensitivity events. Additionally, Clostridioides difficile-associated diarrhea (CDAD), which can develop into pseudomembranous colitis, is listed as a potential serious reaction that may occur during or even after treatment. Seizures and other Central Nervous System (CNS) effects are also documented, particularly with high exposure.

Safety Considerations for Specific Populations

The official labeling specifies that patients with impaired renal function require close monitoring because the drug's accumulation increases the risk of CNS effects, including seizures. Furthermore, individuals with a known history of hypersensitivity to penicillin or other beta-lactam antibiotics are noted to have a safety constraint due to the potential for cross-reactivity.

Time and Interaction Safety Notes

Certain hematologic effects, such as a drop in blood cell counts, have been associated with prolonged treatment (over 10 days). Safety restrictions are also noted when Ceftax is used alongside certain other medications, such as aminoglycosides or potent diuretics, due to the potential for enhanced nephrotoxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations and mandated emergency actions for an overdose of Ceftax (Cefotaxime), as strictly stated in governmental regulatory documents.

Overdose Scope Official Regulatory Information
Documented Manifestations Overdose can result in neurotoxicity, which includes encephalopathy, impairment of consciousness, and abnormal movements. The most severe manifestation listed is convulsions or seizures.
Severe Circumstances Life-threatening arrhythmia has been reported in rare cases associated with very rapid intravenous administration through a central venous catheter.
Specific Risk Factor The risk of neurotoxicity is significantly increased, particularly in patients with renal insufficiency (kidney impairment), due to impaired clearance of the drug.
Supportive Management Treatment is officially defined as symptomatic and supportive. No specific antidote is known or listed in the regulatory documents.

Mandatory Emergency Actions

Immediate medical help is required when the person experiencing the overdose presents with specific severe signs. You must immediately call emergency services if the individual has collapsed, has a seizure, cannot be awakened, or is experiencing trouble breathing. Furthermore, regulatory instructions state to contact your doctor immediately prior to continuing treatment if any neurotoxicity reactions, such as impairment of consciousness or abnormal movements, are observed.

Therapeutic Uses of Ceftax

What Ceftax Treats: Main Uses and Benefits

This medication is commonly used when short-term symptomatic assistance is needed to address conditions presenting with systemic or localized discomfort that are caused by bacterial infections. Application occurs in contexts marked by increased discomfort and helps ease the overall symptom burden, including symptoms related to systemic imbalance like high fever and severe physical discomfort. This use may assist with achieving symptom stabilization, which supports general well-being during symptomatic phases.

Ceftax is considered relevant for easing symptoms across a range of serious bacterial conditions. These conditions typically include pneumonia, severe infections of the urinary tract or kidneys, meningitis (infection of the brain and spinal cord lining), sepsis (bloodstream infection), and infections affecting the bones, joints, or skin. It is applied across domains where additional symptomatic support is needed to manage symptom clusters that may be intense or disruptive. It also is applied in addressing the symptomatic burden that can occur following high-risk surgical procedures (prophylaxis).

“It offers symptomatic relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.”


Quick Fact: Relief for Systemic Symptoms Ceftax is used for managing symptoms associated with acute episodes, such as high fever and severe discomfort, and is relevant when supportive symptom management is appropriate.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ceftax?

This section outlines the official population eligibility rules for Ceftax (Cefotaxime), based strictly on governmental regulatory documents.


Contraindications and Non-Eligibility

Ceftax must not be used (is contraindicated) in the following populations:

  • Patients with a known history of hypersensitivity to cefotaxime or any other cephalosporin antibiotic.
  • Patients with a history of an immediate or severe allergic reaction to any other beta-lactam antibacterial agents (such as penicillins).
  • Preterm neonates.
  • Full-term neonates who have hyperbilirubinemia or are receiving intravenous calcium-containing solutions.

Population Eligibility Rules

Age Group Eligibility Status Restrictions/Caution
Adults and Adolescents Allowed Standard use permitted.
Pediatric Patients Allowed Use permitted from 28 days of age.
Older Adults Allowed Renal function must be monitored.
Pregnancy/Lactation Conditional Use Use is conditional, recommended only if clearly needed.

Conditions Requiring Caution

Use requires special caution or monitoring in individuals with a history of gastrointestinal disease, particularly colitis, and in patients with severe renal impairment, which necessitates a reduction in the total daily dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ceftax (Cefotaxime) focuses on specific pharmacokinetic and pharmacodynamic constraints as documented in regulatory labeling.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Official Interaction Description Type
Probenecid Increases Ceftax plasma concentration and reduces total clearance by interfering with renal tubular transfer. Pharmacokinetic (PK)
Aminoglycosides (e.g., Gentamicin, Amikacin) and Potent Diuretics (e.g., Furosemide) Ceftax may potentiate the nephrotoxic effects of these co-administered drugs. Pharmacodynamic (PD)
Chloramphenicol Potential for pharmacodynamic antagonism that may reduce the effect of Ceftax. Pharmacodynamic (PD)

Mandatory Administration Constraints

Two critical administration constraints are established in regulatory documents based on incompatibility and safety:

  • Aminoglycosides must not be mixed with Ceftax in the same syringe or perfusion fluid due to pharmaceutical incompatibility.
  • Intravenous (IV) administration is contraindicated if the Ceftax solution has been reconstituted using Lidocaine, which is reserved for the intramuscular route.

Population-Specific Caution

Official labeling advises that patients with pre-existing renal impairment and the elderly require closer monitoring of kidney function when receiving Ceftax concurrently with nephrotoxic drugs or Probenecid, as these interactions may be more clinically significant in these populations.

Mechanism of Action

Ceftax is a beta-lactam antibiotic that exerts its pharmacodynamic action by interfering with bacterial cell wall synthesis. The active molecule acts as a substrate analog, binding covalently and irreversibly to bacterial enzymes known as Penicillin-Binding Proteins (PBPs). These PBPs are critical transpeptidases responsible for the final cross-linking of linear peptidoglycan chains, which forms the stabilizing mesh layer of the bacterial cell wall.

By acylating the active site of the PBPs, Ceftax inhibits the transpeptidase reaction necessary for structural integrity. This mechanistic cascade results in the formation of a defective and incomplete peptidoglycan layer. The compromised cell wall structure leaves the bacterial cell vulnerable to high internal osmotic pressure. This stress triggers the activation of bacterial autolytic enzymes, which further degrade the structural layer. The system-level physiological consequence is bacteriolysis, which involves the rupture of the bacterial cell membrane and loss of viability.

Dosage and Administration Information

Ceftax (cefotaxime) is strictly administered through the parenteral route as a solution reconstituted from a powder for injection. The approved methods are intravenous (IV) injection or infusion and intramuscular (IM) injection. The specific use pattern is dictated by the required total daily dose, which is based on the severity of the condition being managed.

For adults, standard dosing starts at 1 gram administered every 12 hours for less severe conditions. For severe or life-threatening scenarios, the dose increases to 2 grams given as frequently as every 4 hours, up to a maximum daily dose of 12 grams. Pediatric dosing is calculated using a weight-based regimen.

Administration requires the powder to be dissolved using approved sterile diluents. IV bolus injections must be delivered slowly over 3 to 5 minutes, while intermittent infusions take 20 to 60 minutes. When the IM route is used, the medicine may be prepared with 1% lidocaine to mitigate pain, though solutions containing lidocaine must not be administered intravenously. The duration of use is typically short-term, often continuing for 3 to 4 days after symptoms have resolved. A key procedural adjustment is required for patients with severe renal impairment, where the labeled maintenance dose is reduced by half following the initial loading dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Ceftax


Evidence for Use in Severe Systemic Infections and Meningitis

Research has examined Ceftax in the context of critical medical situations, such as bloodstream infections (sepsis) and meningitis (infections of the lining around the brain and spinal cord). The evidence base primarily includes Randomized Controlled Trials (RCTs) and Systematic Reviews. Researchers monitored clinical responses, bacteriological eradication rates (clearing the infectious organism), and outcomes related to patient survival and hospital stay duration. This research was conducted during periods of increased symptom activity where systemic or functional imbalance was observed.

In these studies, findings describe patterns observed in the studies related to measured outcomes such as microbiological clearance. For meningitis, research explored whether the medicine helped clear the infectious bacteria from the cerebrospinal fluid (CSF). Studies monitored measurements of mortality and hospital stay length, often including comparisons with other anti-infective agents.

Evidence for Use in Site-Specific Complicated Infections

Ceftax was evaluated in studies focused on specific site infections, including severe pneumonia, complicated kidney infections, and infections within the abdominal lining, such as spontaneous bacterial peritonitis (SBP). For these conditions, the research often includes comparative trials where Ceftax was studied alongside other antibiotics in research exploring short-term symptom changes.

For SBP, trials explored outcomes related to infection resolution, using specific laboratory measures—like the reduction of white blood cells in the abdominal fluid—as a main measured outcome. Scientific reviews note that for SBP, this medicine data show patterns related to measured success metrics for this condition.

Research Gaps and Areas of Uncertainty

Research explores the issue of antimicrobial resistance, and some studies note that the measured outcomes of Ceftax data show patterns related to the emergence of certain resistant bacterial strains. Furthermore, evidence is limited for long-term outcomes, such as sustained daily functioning, as follow-up durations were often limited to the immediate post-treatment period. Getting accurate drug exposure in critically ill patients presents a constant challenge, meaning evidence quality varies across studies depending on the specific patient setting.

Key Studies & References

  1. WHO Model List of Essential Medicines - Cefotaxime

Frequently Asked Questions (FAQ)

Common questions about Ceftax (FAQ)


Q: How long does it usually take to notice a difference after starting Ceftax?

Official patient instructions indicate that a patient may begin to experience improvement during the first few days of treatment with Ceftax. If the condition does not improve or if symptoms worsen, patients are typically advised to contact a healthcare professional.


Q: Can Ceftax be taken with commonly used pain relievers?

Regulatory documents list specific prescription drug classes, such as Probenecid and certain antibiotics, that have known interactions with Ceftax. Official interaction documents do not commonly list or warn against general over-the-counter (OTC) pain relievers; however, all co-administered medications should be reviewed with a healthcare provider.


Q: Are there specific food or drinks that should be avoided when taking Ceftax?

Official instructions indicate that patients can generally continue their normal diet while receiving Ceftax, unless a healthcare professional provides specific dietary instructions.


Q: Does Ceftax interact with birth control pills?

Official regulatory documents list several known drug-drug interactions for Ceftax. Hormonal contraceptives, such as birth control pills, are not commonly listed as a specific interaction in the authoritative product information.


Q: Can children use Ceftax, and is the dosage different?

Yes, Ceftax is permitted for use in pediatric patients starting from 28 days of age. Official documents state that the dosage for children is calculated using a weight-based regimen, and the total daily dose is divided into multiple administrations.


Q: What is the typical time frame for a course of Ceftax treatment?

The duration of treatment is guided by the specific condition being managed. As a general rule, the medicine is administered for a further three to four days after the symptoms have completely improved or resolved.


Q: Are any vitamins or supplements known to interact with Ceftax?

Official regulatory documents outline interactions with prescription drugs but do not typically include general vitamins or supplements as specific interacting substances. Patients are generally advised to discuss all products, including vitamins and supplements, with their healthcare provider.


Q: What is the risk of an allergic reaction to Ceftax?

The official safety documentation lists a range of possible hypersensitivity reactions. These can vary from common issues like a rash or itching to rare but serious reactions such as anaphylactic shock. Patients with a known allergy to penicillin or other related antibiotics are specifically noted to have a safety constraint on using this medicine.


Q: If I miss a dose of Ceftax, what does the official patient information say to do?

Official patient instructions advise that if a dose is missed, it should be used as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Official guidance states that a double dose should not be administered to compensate for a missed dose.


Q: Is it true that Ceftax is sometimes called a 'broad-spectrum' drug?

Yes. The official purpose description for Ceftax confirms it is designed to function as a broad-spectrum anti-infective agent. This term indicates its ability to target and manage a wide range of susceptible bacteria that cause serious infections.


Q: What should I do if the side effects of Ceftax seem severe?

Official patient information advises that if serious symptoms (such as swelling of the face, difficulty breathing, or bloody stools) occur, the administration should be discontinued and immediate medical attention sought. The label highlights that reactions such as severe allergic shock or severe diarrhea may require immediate intervention.


Q: Does Ceftax make you more sensitive to the sun?

The official documentation of adverse reactions for Ceftax does not commonly list photosensitivity, which is an increased sensitivity to the sun, as a documented side effect.


Q: Is there a generic version of Ceftax available?

The active ingredient in Ceftax is cefotaxime sodium. This ingredient is available under its generic name and other brand names globally, indicating that generic versions do exist.


Q: Does Ceftax interact with blood thinners?

Official product monographs state that Ceftax may increase the effects of certain blood thinners, such as warfarin. This interaction is described as potentially increasing the risk of bleeding. Official labeling advises that closer monitoring may be necessary for patients receiving a blood thinner.


Q: Are there any special warnings for older adults using Ceftax?

Official labeling advises that older adults require closer monitoring of kidney function. This is particularly relevant when the medicine is used with other drugs that can affect kidney function (nephrotoxic drugs).


Q: What does the FDA or EMA say about the safety profile of Ceftax?

Regulatory agencies like the FDA and EMA have established safety profiles detailing common reactions (such as diarrhea and rash), uncommon reactions (such as headache and dizziness), and rare but serious adverse reactions (such as severe allergic reactions and seizures and severe diarrhea/colitis).


Q: Does Ceftax interact with antacids or acid reflux medications?

Official interaction documents for Ceftax, which is only administered by injection, do not commonly list antacids or general acid reflux medications as a known interaction.


Q: Why is Ceftax sometimes given via injection instead of orally?

Ceftax is only administered by injection (parenteral route) due to poor oral bioavailability, meaning it is not adequately absorbed if taken by mouth. This route is typically necessary to achieve the high drug concentrations needed to treat serious infections effectively.


Q: Is it normal to feel tired or fatigued while on Ceftax?

Official safety documents do not commonly list general tiredness or fatigue as a frequent side effect. However, unusual tiredness or weakness is mentioned in some side effect categories, and uncommon reactions include headache and dizziness.


Q: What are the official recommendations for storing Ceftax?

The unreconstituted powder must be stored at controlled room temperature and protected from light. Once prepared, the stability depends on the temperature, with solutions lasting from 12 to 24 hours at room temperature up to 7 days when refrigerated.


Q: Does drinking alcohol affect the safety or effectiveness of Ceftax?

The official interaction profile does not commonly list a specific interaction or contraindication related to the consumption of alcohol with Ceftax.


Q: What is the difference between Ceftax and a common penicillin-based drug like amoxicillin?

Ceftax belongs to a class of antibiotics called third-generation cephalosporins, which are related to penicillins. Compared to common penicillin-based drugs, cephalosporins are generally described as offering a broader spectrum of activity and enhanced resistance to certain bacterial enzymes.


Q: Are there any specific liver warnings associated with the use of Ceftax?

Official safety data lists transient elevations in liver enzymes as an uncommon adverse reaction. Official labeling notes that liver chemistry monitoring may be indicated when Ceftax is used in individuals with underlying liver disease.


Q: Does Ceftax have a warning about drug-induced diarrhea?

Yes. Official patient guidance states that Ceftax injection may cause diarrhea, which can sometimes be severe. A serious reaction known as Clostridioides difficile-associated diarrhea (CDAD) is also listed as a potential risk.


Q: What are the documented effects of Ceftax on gut bacteria?

While the official label does not detail general effects on the gut microbiome, it does document the potential for Clostridioides difficile-associated diarrhea (CDAD) to occur. This serious reaction is a known consequence of how antibiotics can disrupt the natural balance of bacteria in the gut.


Q: Is the name 'Ceftax' used globally, or does it have other names?

The active ingredient in Ceftax, Cefotaxime, is internationally recognized and used. It is marketed under several brand names globally, including brands such as Claforan and Tolycar.


Q: Can Ceftax be used to prevent infections before a surgery?

Official documentation indicates that Cefotaxime has been studied for use in preventing postsurgical infections (prophylaxis). This use is generally noted in professional monographs, but the role of third-generation cephalosporins in prophylaxis is sometimes noted as still being reviewed.


Q: Are there specific groups of patients where Ceftax is studied less often?

The official research overview notes that evidence is limited for long-term outcomes, as follow-up durations are often short. Additionally, obtaining accurate drug exposure measurements in critically ill patients is a documented challenge, suggesting evidence quality can vary across these specific patient settings.


Q: What are the typical non-serious side effects that patients report with Ceftax?

The typical non-serious side effects documented in official safety information include common reactions like diarrhea, rash, and injection site reactions (pain or inflammation). Uncommon but non-serious effects include headache and dizziness.


Q: Are there any warnings about mental or mood changes while taking Ceftax?

While general mood changes are not commonly listed, the official safety label includes warnings for potential Central Nervous System (CNS) effects. These effects include seizures, particularly when the drug is used in high doses or in patients with kidney impairment, and symptoms like confusion.

How should Ceftax be stored and disposed of?

Ceftax (Cefotaxime Sodium for Injection) must be stored and handled according to specific regulatory conditions to maintain its integrity.

Storage and Stability

The unreconstituted powder must be stored at Controlled Room Temperature, which is between 20 C to 25 C (68 F to 77 F), and must be protected from light and elevated temperatures by remaining in the outer carton.

Once the powder is reconstituted, stability is temperature-dependent:

  • Refrigerated Solutions (at or below 5 C) are stable for up to 7 days.
  • Room Temperature Solutions (at or below 22 C) are stable for approximately 12 to 24 hours.
  • Frozen Solutions (at -20 C or below) are stable for up to 13 weeks but must not be refrozen after thawing.

Disposal Requirements

All forms of the medicine must be kept out of the sight and reach of children.

Unused or expired product must be disposed of in accordance with all applicable local requirements and should not be released into the environment or wastewater. Used needles and syringes (sharps) must be placed immediately into an FDA-cleared sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ceftax found in:

A-Z Index: